Aspirin resistance in neurovascular diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F14%3A10294672" target="_blank" >RIV/00216208:11150/14:10294672 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/14:10294672

Výsledek na webu

<a href="http://actamedica.lfhk.cuni.cz/57/4/0157/" target="_blank" >http://actamedica.lfhk.cuni.cz/57/4/0157/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14712/18059694.2015.81" target="_blank" >10.14712/18059694.2015.81</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Aspirin resistance in neurovascular diseases

Popis výsledku v původním jazyce

Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinicalnon-responsiveness to aspirin treatment and a high-risk of atherothrombotic complications using two interpretable and independent methods (aggregation and PFA 100). The second objective was to find the correlation between both assays and to evaluate theresults in groups at risk for various cerebrovascular diseases. Material and methods: Laboratory tests of aspirin resistance were performed in 79 patients with clinical non-responsiveness to aspirin treatment suffering from neurovascular diseases. Patients were divided into the two groups: expected low risk for aspirin resistance due to the first manifestation of a neurovascular disease (n = 34) and expected high risk due to the second clinical manifestation of a neurovascular disease (n

Název v anglickém jazyce

Aspirin resistance in neurovascular diseases

Popis výsledku anglicky

Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinicalnon-responsiveness to aspirin treatment and a high-risk of atherothrombotic complications using two interpretable and independent methods (aggregation and PFA 100). The second objective was to find the correlation between both assays and to evaluate theresults in groups at risk for various cerebrovascular diseases. Material and methods: Laboratory tests of aspirin resistance were performed in 79 patients with clinical non-responsiveness to aspirin treatment suffering from neurovascular diseases. Patients were divided into the two groups: expected low risk for aspirin resistance due to the first manifestation of a neurovascular disease (n = 34) and expected high risk due to the second clinical manifestation of a neurovascular disease (n

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Medica (Hradec Králové)

ISSN

1211-4286

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

157-161

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84938935216